Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.48 |
| ▸ | FCER2 | P06734 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 11/20 | 0.48 |
| ▸ | MMP8 | P22894 | 11/20 | 0.48 |
| ▸ | MMP2 | P08253 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558607 | 0.86 | MAPT (0.49) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5558630 | 0.73 | MMP9 (0.80) | MMP1FCER2MMP9MMP8MMP2 | |
| SCHEMBL5557538 | 0.73 | MMP9 (0.80) | MMP1FCER2MMP9MMP8MMP2 | |
| SCHEMBL5556787 | 0.73 | ERAP2 (0.69) | MMP1FCER2MMP9MMP8MMP2 | |
| SCHEMBL5558476 | 0.71 | MMP9 (0.60) | MMP1FCER2MMP9MMP8MMP2 | |
| SCHEMBL5556727 | 0.70 | MMP9 (0.59) | MMP1FCER2MMP9MMP8MMP2 | |
| SCHEMBL5018918 | 0.70 | ALDH1A1 (0.46) | KDM4EMEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5552501 | 0.69 | MMP9 (0.55) | MMP1FCER2MMP9MMP8MMP2 | |
| SCHEMBL12804151 | 0.68 | POLB (0.51) | MEN1KMT2ASMN1; SMN2MAPTCHRNA7 | |
| SCHEMBL5552823 | 0.68 | MMP9 (0.62) | MMP1FCER2MMP9MMP8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP1 950/4885FCER2 3098/4885MMP9 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.